Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market : Industrial Analysis, Growth, Segmentation and Forecast-2019-2027
- POSTED ON Friday, June 4, 2021
The Global Market for Lysosomal Acid Lipase (LAL) Deficiency Treatment was valued $xx Mn in 2019 and is expected to reach $xx Mn in 2027, at a CAGR of xx%.Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Introduction and Overview
Lysosomal Acid Lipase deficiency (LAL-D) is an inherited, ultra-rare, autosomal recessive Lysosomal storage disease. The deficiency is caused due to mutations in the LAL gene. These alterations in the gene, prevent it from breaking down the cholesteryl esters and triglycerides. As a result, there is accumulation of lipids in the liver, spleen and the walls of blood vessels. The deficiency of LAL enzyme causes the autosomal recessive disorders- Wolman Disease (WD) and Cholesteryl Ester Storage Disease (CESD).
FDA approval for Sebelipase (Kanuma) - the first drug for treating LAL-D boosted the market growth. The drug was developed using the Enzyme Replacement Therapy (ERT) which enhanced the growth of ERT segment. At present, kanuma is the only drug approved for the treatment of Wolman and CESD. The rising cases of liver transplant is in turn elevating the LAL-D market. However, disease diagnosis remains poor, as majority of people are unaware and remain undiagnosed. There is a strong need of awareness about timely diagnosis of the disease. In addition to this, inadequacy for therapeutics and high treatment costs are major restraints for market growth.
The report covers the detailed analysis of global market for Lysosomal Acid Lipase (LAL) deficiency treatmentwith the classifications of the market based on therapy type, drug type, Disease indication and region. Analysis of past market dynamics from 2016 to 2019 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it.The report has profiled seven key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on Lysosomal Acid Lipase (LAL) deficiency market are covered in the report.Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Segment Analysis
The drug type segment is expected to continue its dominance in the forecast period. In 2019 the segment was valued $xx Mn and is expected to reach $xx Mn in 2027. As Kanuma is the only FDA approved drug for the treatment of LAL-D, its market is expected to grow continuously along with ERT. Lack of other therapies for treatment ofthe disease, provides a huge opportunity for the key players to invest in finding new therapies. Emergence and approval of new treatments will eventually boost the market growth.
As the prevalence of this deficiency increases, the need for treatments such as liver transplantation and haematopoietic stem cell therapy will increase, gradually leading the market to grow. The therapy type segment is also expected to rise at a CAGR of xx% in the forecast period. Not only for LAL-D treatment, but the market for therapy segment is anticipated to grow due to other disease complications too.
To know about the Research Methodology :- Request Free Sample ReportGlobal Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Segmentation
The Global LAL-D market is segmented based on-Type of therapy
• Liver Transplant• Haematopoietic Stem Cell TransplantType of Drug
• Statins and Other Dyslipidemia Drugs• Sebelipasealfa (Kanuma)Disease indication
• Wolman Disease• Cholesteryl Ester Storage Disease (CESD)
For more information of visit:https://www.maximizemarketresearch.com/market-report/global-lysosomal-acid-lipase-lal-deficiency-treatment-market/82146/Scope of Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market :Inquire before buying
Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Regional Insights
North America is expected to dominate the market in the forecast period owing to the rapid innovations in healthcare domain, drug development and increasing economy. The approval of Alexion’s Kanuma boosted the market growth in this region. Also, presence of top key players is a major reason for the market to elevate.
Europe is expected to be the second largest for LAL-D treatment market. European Commission granted permission for marketing of Kanuma for the treatment of LAL-D patients. This is expected to fuel the market growth in this region.Key players operating the Global LAL-D market
• Alexion Pharmaceuticals Inc• AstraZeneca plc• Merck & Co, Inc• Pfizer, Inc• Teva Pharmaceutical Industries Ltd• Thermo Fisher Scientific• Lonza Group Ltd
The objective of the report is to present a comprehensive analysis of the Global Lysosomal Acid Lipase (LAL) deficiency market of all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Lysosomal Acid Lipase (LAL) deficiency market dynamics, structure by analysing the market segments and project the Global Lysosomal Acid Lipase (LAL) deficiency market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Lysosomal Acid Lipase (LAL) deficiency market make the report investor’s guide.
This Report Is Submitted By : Maximize Market Research CompanyCustomization of the report:Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.About Maximize Market Research:Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Global Incontinence Skin Care and Body Wash Market was valued US$ XX Bn in 2019 and is expected to r..
Asia Pacific Active Pharmaceutical Ingredients Market is expected to reach USD XX Bn by 2027 from US..